Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice - PubMed
6 hours ago
- #diabetes
- #atherosclerosis
- #gli-1 agonists
- The study examines the anti-atherosclerotic effects of tirzepatide, a dual GIP/GLP-1 receptor agonist, compared to semaglutide, a GLP-1 agonist, in ApoE knockout mice.
- In early diabetes groups, both drugs significantly reduced aortic plaque formation, with modest improvements in glucose and lipid levels, while no significant vascular effects were seen in late diabetes or non-diabetic groups.
- Tirzepatide notably decreased inflammatory mediators such as Mcp-1, Il-6, I-cam, and Cd68, indicating stronger anti-inflammatory effects; anti-inflammatory actions were also observed in non-diabetic mice, suggesting vascular protection may occur independently of metabolic control.
- Findings suggest that tirzepatide has anti-atherosclerotic effects comparable to semaglutide, highlighting the potential vascular benefits of dual incretin receptor agonism for cardiovascular risk reduction, though further research on the specific role of GIP signaling is needed.